Continuous infusion of resolvin D2 in combination with Angiotensin-II show contrary effects on blood pressure and intracardiac artery remodeling.

Autor: Olsen MB; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: maribol@medisin.uio.no., Louwe MC; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Yang K; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Øgaard J; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Dahl TB; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Gregersen I; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Alfsnes K; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Lauritzen KH; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Murphy SL; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Ahmed MS; Institute for Surgical Research, Oslo University Hospital, Oslo, Norway., Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway., Vinge LE; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institute for Surgical Research, Oslo University Hospital, Oslo, Norway; Department of Medicine, Diakonhjemmet Hospital, Oslo, Norway., Yndestad A; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Holven KB; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway., Halvorsen B; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Fosshaug LE; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.

Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Nov 12; Vol. 733, pp. 150706. Date of Electronic Publication: 2024 Sep 15.

The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure.

Autor: Holt MF; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Michelsen AE; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Shahini N; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Bjørkelund E; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Bendz CH; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Massey RJ; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Schjalm C; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway., Halvorsen B; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Broch K; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; K.G. Jebsen Cardiac Research Center, Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway., Ueland T; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Faculty of Health Sciences, K. G. Jebsen Thrombosis Research Center, University of Tromsø - The Arctic University of Norway, Tromsø, Norway., Gullestad L; Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; K.G. Jebsen Cardiac Research Center, Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway., Nilsson PH; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.; Linnaeus Centre for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden., Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway., Mollnes TE; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.; Faculty of Health Sciences, K. G. Jebsen Thrombosis Research Center, University of Tromsø - The Arctic University of Norway, Tromsø, Norway.; Research Laboratory, Nordland Hospital, Bodø, Norway.; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway., Louwe MC; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Publikováno v: Frontiers in immunology [Front Immunol] 2021 Dec 24; Vol. 12, pp. 800978. Date of Electronic Publication: 2021 Dec 24 (Print Publication: 2021).

Absence of NLRP3 Inflammasome in Hematopoietic Cells Reduces Adverse Remodeling After Experimental Myocardial Infarction.

Autor: Louwe MC; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Olsen MB; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Kaasbøll OJ; Institute for Surgical Research, Oslo University Hospital, Oslo, Norway., Yang K; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Fosshaug LE; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Alfsnes K; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Øgaard JDS; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Rashidi A; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Skulberg VM; Institute for Experimental Medical Research, Oslo University Hospital Ullevål, Oslo, Norway., Yang M; Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway., de Miranda Fonseca D; PROMEC Core Facility for Proteomics and Metabolomics, Norwegian University of Science and Technology, Trondheim, Norway., Sharma A; PROMEC Core Facility for Proteomics and Metabolomics, Norwegian University of Science and Technology, Trondheim, Norway., Aronsen JM; Institute for Experimental Medical Research, Oslo University Hospital Ullevål, Oslo, Norway.; Bjørknes College, Oslo, Norway., Schrumpf E; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway.; Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway., Ahmed MS; Institute for Surgical Research, Oslo University Hospital, Oslo, Norway., Dahl CP; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway., Nyman TA; Department of Immunology, Institute of Clinical Medicine, University of Oslo and Rikshospitalet Oslo, Oslo, Norway., Ueland T; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Melum E; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway.; Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Section for Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway., Halvorsen BE; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Bjørås M; Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Attramadal H; Institute for Surgical Research, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Sjaastad I; Faculty of Medicine, University of Oslo, Oslo, Norway.; Institute for Experimental Medical Research, Oslo University Hospital Ullevål, Oslo, Norway., Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway.; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway., Yndestad A; Faculty of Medicine, University of Oslo, Oslo, Norway.

Publikováno v: JACC. Basic to translational science [JACC Basic Transl Sci] 2020 Dec 09; Vol. 5 (12), pp. 1210-1224. Date of Electronic Publication: 2020 Dec 09 (Print Publication: 2020).

Complement component C3 and the TLR co-receptor CD14 are not involved in angiotensin II induced cardiac remodelling.

Autor: Shahini N; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway., Schjalm C; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Nilsson PH; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Linnaeus Centre for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden., Holt MF; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway., Øgaard JDS; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway., Lien E; UMass Medical School, Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, Worcester, MA, USA; Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Ahmed MS; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Attramadal H; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Institute for Surgical Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Center of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Yndestad A; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway., Mollnes TE; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Center of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway; Research Laboratory, Nordland Hospital, Bodø, and K.G. Jebsen TREC, University of Tromsø, Tromsø, Norway. Electronic address: t.e.mollnes@gmail.com., Louwe MC; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway.

Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2020 Mar 19; Vol. 523 (4), pp. 867-873. Date of Electronic Publication: 2020 Jan 16.

NLRP3 Inflammasome: A Novel Player in Metabolically Induced Inflammation-Potential Influence on the Myocardium.

Autor: Sokolova M; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway., Ranheim T; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, The Faculty of Medicine, University of Oslo, Oslo, Norway., Louwe MC; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway., Halvorsen B; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, The Faculty of Medicine, University of Oslo, Oslo, Norway., Yndestad A; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, Oslo, Norway.; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2019 Oct; Vol. 74 (4), pp. 276-284.